FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to peptide containing less than 15 amino acids with the capability of inducing a cytotoxic T-cell (CTC) in the presence of antigen-presenting cell(s) expressing HLA-A*1101. Polynucleotide encoding the specified peptide; a composition, an emulsion, a kit containing the specified peptide; antigen-presenting cells containing the specified peptide are disclosed. Methods for the induction of an immune response, treatment or prevention using the specified peptide, a method for peptide screening; the use of a suitable dose of the specified peptide are also disclosed.
EFFECT: invention allows for the effective treatment of diseases associated with HLA-A*1101 factor.
21 cl, 9 dwg, 6 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE DERIVED FROM FOXM1, AND INCLUDING ITS VACCINE | 2016 |
|
RU2738418C2 |
| PEPTIDE, OBTAINED FROM MPHOSPH1, AND INCLUDING ITS VACCINE | 2016 |
|
RU2731099C2 |
| SPECIFIC BINDING MOLECULES | 2020 |
|
RU2825837C2 |
| ARTIFICIAL ANTIGEN-PRESENTING CELLS AND METHODS FOR THEIR APPLICATION | 2018 |
|
RU2763798C1 |
| PEPTIDE OBTAINED FROM GPC3, PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER USING IT, IMMUNITY INDUCER AND METHOD FOR PRODUCING ANTIGEN-PRESENTING CELLS | 2016 |
|
RU2714117C2 |
| T-CELL RECEPTORS SPECIFIC RELATIVELY TO COMPLEX OF TUMOR ANTIGEN NY-ESO-1/HLA-A*02 | 2016 |
|
RU2775394C2 |
| T-CELL RECEPTORS | 2017 |
|
RU2775623C2 |
| IMMUNITY INDUCER | 2016 |
|
RU2758112C2 |
| NEOANTIGENS AND THEIR USE | 2019 |
|
RU2813924C2 |
| NEOANTIGENS AND THEIR APPLICATION | 2019 |
|
RU2805196C2 |
